Many companies saw their stocks soar in 2020 after having started work on COVID 19 vaccines and that was the main reason behind the rally in the Ibio Inc (NYSE: IBIO) stock last year.
IBIO has continued to perform well in 2021 and has delivered gains of 349% so far after iBio flagged off two COVID 19 vaccine programs. Yesterday, the stock climbed further and rallied by as much as 25%.
The initiation of two COVID 19 programs has clearly put the IBIO stock in the radars of many investors. More importantly, in August 2020 the preliminary data from one of the two vaccine studies revealed that it could in fact prove to be effective.
That being said, investors need to keep in mind that there is still a low way to go before iBio can hope to generate any revenue from the products. The launch of clinical trials is only the first step. At this point, the company is funding its activities by offering manufacturing services to smaller companies.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.